Zenith p-Branch覆膜支架前瞻性多中心可行性研究结果
该研究评估了现成Zenith p-Branch覆膜支架治疗无症状近肾或肾周腹主动脉瘤的安全性和可行性,30例患者技术成功率93%,无30天死亡,主要肾动脉通畅率1年和2年均为88.6%±4.4%,支持该装置的安全可行性。
要点
- 技术成功率93%,早期失败与学习曲线相关,培训后未再发生。
- 无30天死亡、动脉瘤破裂、转化或支架断裂。
- 主要肾动脉通畅率1年和2年均为88.6%±4.4%。
核心结论
- 现成Zenith p-Branch装置治疗近肾或肾周腹主动脉瘤安全可行。
研究设计与样本
- 前瞻性、非随机、多中心可行性研究,美国开展,纳入30例无症状近肾或肾周腹主动脉瘤患者。
主要发现
- 技术成功率为93%(28/30),失败发生于最初两例。
- 无30天死亡,随访期间3例死亡均与装置或手术无关。
- 无动脉瘤破裂、转化、核心实验室报告的迁移或支架断裂。
- 主要肾动脉通畅率1年和2年均为88.6%±4.4%。
- 2例(7%)发生肾功能不全,无患者需透析或发生肠系膜缺血。
关键数值与推荐
- 纳入标准为动脉瘤未延伸至肠系膜上动脉远端边缘以上,且肾和内脏动脉解剖符合两种p-Branch配置之一。
- 配置A为肾动脉开窗在同一纵向位置,配置B为肾动脉开窗错位。
临床怎么用
- 对于解剖合适的近肾或肾周腹主动脉瘤,可考虑使用现成Zenith p-Branch装置。
- 需关注肾动脉和肠系膜上动脉的通畅性及二次干预风险。
局限性
- 样本量小(30例),非随机设计,随访时间中等(平均28.7±12.5个月)。
- 包含医生学习曲线,早期结果可能受影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the Cook Zenith p-Branch stent graft (William A. Cook Australia, Brisbane, Queensland, Australia) for the treatment of patients with asymptomatic juxtarenal or pararenal abdominal aortic aneurysms in a prospective, nonrandomized, multicenter, feasibility study conducted in the United States. METHODS: The off-the-shelf p-Branch endograft incorporates a celiac scallop, superior mesenteric artery (SMA) fenestration, and two conical-shaped pivot renal fenestrations. Patients were eligible if the aneurysm did not extend above the distal margin of the SMA and the anatomy of renal and visceral arteries were compatible with one of the two p-Branch configurations (configuration A, renal fenestrations at the same longitudinal position; configuration B, offset renal fenestration). RESULTS: A total of 30 patients (93% men; mean age, 73 years; mean aneurysm diameter, 64.7 ± 11.4 mm) were enrolled from January 2013 to June 2015. The mean follow-up period was 28.7 ± 12.5 months (as of October 2017). The technical success rate was 93% (28/30), with technical failure occurring in the first two study cases (device deliberately repositioned below the renal arteries because of difficulty in cannulating the renal arteries in one and an inability to place a renal stent in the other; both patients survived the procedure and withdrew from the study before the 12-month follow-up visit). No additional technical failures occurred after these first two cases, when an updated physician training and proctoring program was implemented. No 30-day mortality occurred. Of the remaining 28 patients, three died during the follow-up period; none within 30 days and none related to the device or procedure as determined by Clinical Events Committee adjudication. No treated aneurysm ruptures, conversion, or core laboratory-reported migration, or stent fracture were reported. The primary renal artery patency (interval to occlusion or reintervention for stenosis) rate was 88.6% ± 4.4% at 1 and 2 years. Two patients (7%) developed renal insufficiency secondary to a right renal artery stenosis in one patient and progression of chronic renal insufficiency in one patient. No patient required dialysis or developed mesenteric ischemia. Of the 28 patients, nine (32%) had undergone 13 secondary interventions for renal artery occlusion (n = 2), SMA occlusion (n = 1), renal or SMA stenosis (5 interventions in 4 patients), renal stent kinking (n = 1), lower extremity claudication (n = 2 in the same patient), type III endoleak between the p-Branch and renal stent (n = 1), and type II endoleak (n = 1). CONCLUSIONS: These early and intermediate results, which incorporated physician learning curves, support the safety and feasibility of the off-the-shelf Zenith p-Branch device. Follow-up examinations through 5 years will continue to assess the long-term results.
引用
- Farber MA, Oderich GS, Timaran C, et al. Results from a prospective multicenter feasibility study of Zenith p-Branch stent graft. J Vasc Surg. 2019. PMID: 31255472. doi:10.1016/j.jvs.2019.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。